Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lundbeck

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lundbeck's 2013 CNS (central nervous system) sales performance.

AstraZeneca chief on Brexit: “It’s going to be really painful”

AstraZeneca chief on Brexit: “It’s going to be really painful” Teva’s vacant CEO role eventually filled by Lundbeck’s Kåre Schultz.

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma Sankyo, Lundbeck, Asahi Kasei and another undisclosed Japanese partner.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson

Daily Brief: Lundbeck gets new leader, Recordati sold, GSK-backed firm prepares for market

Daily Brief: Lundbeck gets new leader, Recordati sold, GSK-backed firm prepares for market A round-up from pharma, biotech and healthcare. Dunsire named new Lundbeck chief executive. ... Facing declining sales of its older drugs, neuroscience specialists Lundbeck has secured a CEO to help reinvigorate the business.

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment Another orphan drug, Novelion’s Myalepta (metreleptin) also received a positive opinion, for the treatment of leptin deficiency, while Lundbeck and Otsuka’s Rxulti (brexpiprazole) was recommended for the treatment of

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics